New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral...
NEW WAVE ANNOUNCES Closing of Non-Brokered Private Placement of Units
Lancaster Resources Announces Closing Conditions Met for Lake Cargelligo Acquisition
Trillion Energy Announces Debt Settlements
